Differential diagnosis of dementias using in vivo MRI and data-driven disease progression modelling: a case study in Alzheimer's disease and dementia with Lewy bodies

No abstract is available for this paper.

• Publication year

  2025

• Venue

  medRxiv

• Publication date

  2025-10-08

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1101/2025.10.03.25337171
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review.

  2024cited by this paper
• Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra

  2024cited by this paper
• Data-driven modelling of neurodegenerative disease progression: thinking outside the black box

  2024cited by this paper
• MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies

  2023cited by this paper
• Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

  2023cited by this paper
• Transferability of Alzheimer's disease progression subtypes to an independent population cohort

  2023cited by this paper
• Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies

  2023cited by this paper
• Site effects how-to and when: An overview of retrospective techniques to accommodate site effects in multi-site neuroimaging analyses

  2022cited by this paper
• Manual and automated analysis of atrophy patterns in dementia with Lewy bodies on MRI

  2022cited by this paper
• Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

  2022cited by this paper
• Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort

  2022cited by this paper
• Identifying and evaluating clinical subtypes of Alzheimer’s disease in care electronic health records using unsupervised machine learning

  2021cited by this paper
• Ordinal SuStaIn: Subtype and Stage Inference for Clinical Scores, Visual Ratings, and Other Ordinal Data

  2021cited by this paper
• Sequence of clinical and neurodegeneration events in Parkinson’s disease progression

  2021cited by this paper
• Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer’s Disease Pathology

  2021influential reference
• Beyond the average patient: how neuroimaging models can address heterogeneity in dementia

  2021cited by this paper
• Four distinct trajectories of tau deposition identified in Alzheimer’s disease

  2021cited by this paper
• On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer’s disease and Lewy body disease

  2021cited by this paper
• Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners

  2020cited by this paper
• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

  2020cited by this paper
• Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

  2020cited by this paper
• Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution

  2020influential reference
• Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease

  2019cited by this paper
• Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

  2018cited by this paper
• Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders

  2018influential reference
• Heterogeneous patterns of brain atrophy in Alzheimer's disease.

  2018cited by this paper
• CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders

  2018cited by this paper
• HYDRA: Revealing heterogeneity of imaging and genetic patterns through a multiple max‐margin discriminative analysis framework

  2017cited by this paper
• Mixed neuropathologies and associations with domain-specific cognitive decline

  2017influential reference
• Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

  2017cited by this paper
• Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

  2017cited by this paper
• Insular atrophy at the prodromal stage of dementia with Lewy bodies: a VBM DARTEL study

  2017cited by this paper
• Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference

  2017influential reference
• Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers

  2016cited by this paper
• MRIQC: Advancing the automatic prediction of image quality in MRI from unseen sites

  2016cited by this paper
• Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease

  2016cited by this paper
• Lewy body dementias.

  2015cited by this paper
• Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns

  2015cited by this paper
• Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment

  2015cited by this paper
• The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease

  2014influential reference
• APOE ε4 increases risk for dementia in pure synucleinopathies.

  2013cited by this paper
• An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease

  2012cited by this paper
• Apolipoprotein E in Alzheimer's disease and other neurological disorders.

  2011cited by this paper
• Low sensitivity in clinical diagnoses of dementia with Lewy bodies

  2010cited by this paper
• MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths

  2009cited by this paper
• Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.

  2008influential reference
• An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

  2006cited by this paper
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006cited by this paper
• Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both

  2005influential reference
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Automatically parcellating the human cerebral cortex.

  2004cited by this paper
• Phases of Aβ-deposition in the human brain and its relevance for the development of AD

  2002cited by this paper
• Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank

  2002cited by this paper
• α-Synuclein in Lewy bodies

  1997cited by this paper
• A 5-year longitudinal study of the Mini-Mental State Examination in normal aging.

  1997cited by this paper
• Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

  1994cited by this paper
• Gender differences in age effect on brain atrophy measured by magnetic resonance imaging.

  1991influential reference
• Amyloid plaque core protein in Alzheimer disease and Down syndrome.

  1985cited by this paper

• No citing papers are available for this paper.